Health News Highlights: Gene Therapy, CVS Operational Overhaul, Marburg Virus

This summary covers recent health news, including the slow adoption of gene therapy for sickle cell, Glenview Capital's proposal to improve CVS operations, and Rwanda's battle with the Marburg virus. Student Zoe Davis highlights challenges sickle cell patients face, while Glenview meets CVS, and Rwanda confirms six deaths from Marburg.

In recent health news, gene therapy adoption for sickle cell disease remains slow. Case in point: Zoe Davis, a college student, is refraining from trying new therapies despite frequent hospital visits due to severe pain.

Meanwhile, Glenview Capital Management aims to meet with CVS Health executives to suggest operational improvements. Larry Robbins, who heads the hedge fund, holds a $700 million stake in CVS.

Additionally, Rwanda has reported six fatalities and 20 cases of Marburg virus, as per Health Minister Sabin Nsanzimana. Most victims are healthcare workers in intensive care.

(With inputs from agencies.)